news
VISIBLE aims to better understand experience of psoriasis for people of colour
Janssen has announced plans to initiate a large-scale study into the impact of psoriasis among black, Hispanic, Asian, indigenous and other people of colour.
List view / Grid view
Psoriasis (PsO)
news
Tremfya® ranks highest for skin clearance in psoriatic arthritis patients
Newly published Network Meta-Analysis (NMA) from Janssen indirectly compares all published Phase III data for approved treatments for adults with active Psoriatic Arthritis (PsA).
article
Microneedle patch with precise vancomycin drug dose against MRSA skin infections
Effective vancomycin concentrations can be delivered locally to methicillin-resistant Staphylococcus aureus (MRSA)-infected sites of the skin with the use of miniaturised needles. This presents opportunities for targeted delivery of medication for focal skin diseases. Here, Georgios A Sotiriou and Liv Eidsmo of the Karolinska Institutet discuss some of them.
article
Technologies and tactics for accelerating end-to-end biologic drug development
Creating new biologic drugs from early research is a complex process, but certain development methodologies and practices are proving to reach clinical and commercial goals faster. In this article, Seahee Kim from Samsung Biologics provides insight into how contract development and manufacturing organisations (CDMOs) are applying new and effective methodologies…
article
New regulatory guidance could lead to UK biosimilar boom
New guidance on the licensing of biosimilar products that reduces unnecessary clinical trials is expected to put the UK ahead of Europe and facilitate a boom in these essential life-saving medicines, creating greater patient access and saving the National Health Service (NHS) hundreds of millions of pounds. It could also…
news
EMA human medicines committee meeting highlights, June 2021
Drugs recommended for approval by the European Medicines Agency’s human medicines committee included a gene therapy and two generics, among five others.
news
EC approves first high concentration, low-volume adalimumab biosimilar
YuflymaTM (CT-P17) has been approved for the treatment of thirteen chronic inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and psoriatic arthritis, in Europe.
news
Cosentyx® (secukinumab) meets clinical trial endpoints
Cosentyx®, a treatment for an inflammatory disease has met its primary endpoints in patients during a Phase III trial.
news
FDA approves label update of Cosentyx to include scalp psoriasis
The FDA has approved a label update for Cosentyx, the first interleukin-17A inhibitor approved to treat moderate-to-severe plaque psoriasis...
news
NICE approves 3 drugs for treating plaque psoriasis in children
NICE has approved adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer) and ustekinumab (Stelara, Janssen) for treating plaque psoriasis in children...
news
Novartis’ Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
15 March 2017 | By Niamh Marriott, Junior Editor
Moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear skin following relapse during a treatment pause...
article
P is for Psoriasis
5 December 2016 | By Niamh Louise Marriott, Digital Editor
P is for Psoriasis - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...
news
Novartis’ plaque psoriasis drug keeps skin clear 4 years post treatment
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The aim of Novartis' plaque psoriasis treatment is clear skin and was achieved by 68.5% of patients at Year 1 and this high rate was maintained to Year 4...
news
Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5
18 July 2016 | By Victoria White, Digital Content Producer
At an estimated $4billion a year, the reference product, Humira, is among the European Union's largest single drug expenditures...
news
AbbVie announces study data for Humira in fingernail psoriasis
7 July 2016 | By Victoria White, Digital Content Producer
Nearly half of adult patients treated with Humira achieved at least a 75% improvement in their fingernail psoriasis compared to patients receiving placebo...
